The positive real-world data and pediatric trial results support AUCATZYL's efficacy and safety profile. The company's strategy to expand into frontline therapy could significantly increase its addressable market. Monitor for further clinical data and potential regulatory submissions.
Price Chart
Executive Summary
Autolus Therapeutics held an investor event highlighting real-world data and clinical trial results for its CAR-T therapy AUCATZYL (obe-cel) in acute lymphoblastic leukemia (ALL). The presentation featured positive real-world outcomes from the ROCCA registry, pediatric data from the CATULUS trial, and strategic plans to expand into frontline treatment. The event emphasized the therapy's safety profile, efficacy, and potential to redefine treatment paradigms.
Key Facts
- ROCCA registry data shows 95% response rate in 91 patients treated with obe-cel
- CATULUS Phase Ib trial showed 95.5% overall response rate in pediatric patients
- Obe-cel demonstrated low rates of high-grade CRS and ICANS (8.7% each)
- Median vein-to-vein time of 44 days reported for AUCATZYL
- Company highlighted potential to expand into frontline consolidation therapy for adult ALL
Financial Impact
Positive data presentation with potential to expand market opportunity
Risk Factors
- Clinical trial data is preliminary and from small patient populations
- Real-world data may not reflect controlled trial conditions
- Frontline therapy expansion is still in planning stages
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001730463-26-000043 |
| Document: autl-20260408.htm | 0001730463-26-000043 |
| Document: 0001730463-26-000043-index-headers.html | 0001730463-26-000043 |
| Document: 0001730463-26-000043-index.html | 0001730463-26-000043 |
| Document: 0001730463-26-000043.txt | 0001730463-26-000043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 12, 2026 20d ago | S-3 | $1.94 $1.94 | · 0.00% | ▼ −0.11% | $1.78 (−8.25%) |
Aug 11, 2026 7w ago | 8-K | $2.33 $2.29 | ▼ −1.72% | ▼ −1.31% | $1.78 (−23.61%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Jun 12, 2026 16w ago | Press Release | $1.56 $1.51 | ▼ −3.21% | ▼ −3.88% | $1.78 (+14.10%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.56 $1.53 | ▲ +1.92% | ▲ +2.36% | $1.78 (−14.10%) |
Jun 9, 2026 16w ago | 8-K | $1.46 $1.50 | ▼ −2.74% | ▼ −0.33% | $1.78 (−21.92%) |
May 21, 2026 19w ago | Press Release | $1.70 $1.84 | ▲ +8.24% | ▲ +6.58% | $1.78 (+4.71%) |
May 14, 2026 20w ago | 8-K | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
May 14, 2026 20w ago | Press Release | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access